Autolomous LTD, a developer of critical manufacturing management systems for cell and gene therapies, received a loan from UK Research and Innovation (UKRI), the public innovation agency, to help address manufacturing challenges. 
 
Autolomous will work to expedite development of AutoloMATE-Assist, its digital batch verification technology for cell and gene therapies (CGT). The project began in April 2021 and is expected to last 24 months. 
 
AutoloMATE-Assist is the third module from Autolomous’ digital platform AutoloMATE. This digital platform aims to address efficiency, scalability and process streamlining of the GMP manufacturing and batch verification of cell & gene therapies. The other AutoloMATE modules are AutoloMATE-eBMR, which digitizes batch manufacturing records, and AutoloMATE-CLOCK that provides scheduling of all critical manufacturing variables.
 
The completion of a digital batch verification solution will aims to help with the scale up of cell and gene and advanced therapies. Currently, paper based batch verification creates bottlenecks in the cell and gene therapy manufacturing sector. The alleviation of this bottleneck will be key as more advanced therapies progress through clinical stages into commercialization. 
 
“This support from UKRI demonstrates the critical consideration given to batch verification as part of the ever-expanding CGT infrastructure,” said Alexander Seyf, CEO, Autolomous. “This loan will enable Autolomous to expedite our development of a critical part of our end to end solution for cell and gene therapy manufacturers. It will provide this sector with critically-needed automation in the supply chain, supporting a safe and controlled delivery of more therapies to more patients.”